(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
JFK's granddaughter reveals terminal cancer diagnosis, criticizes cousin RFK Jr. - 2Step by step instructions to Streamline Your Dozing Involvement in a Savvy Bed
- 3Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
- 4Instructions to Perform Fundamental Upkeep on Your Slam 1500.
- 5Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- The most effective method to Arrange a Higher Medical caretaker Pay During Your Next New employee screening
- New York to require social media platforms to display mental health warnings
- 5 Home Improvement Styles: Decision in favor of Your #1
- Which Diet Prompts the Incomparable Wellbeing Results?
- Trying to improve your health and wellness in 2026? Keep it simple
- A Couple of Reasonable Guitars for 2024
- Chinese mega embassy could bring security advantages, says No 10
- Congolese rape survivors search in vain for medicine after USAID cuts
- Unpaid caregiving work can feel small and personal, but that doesn’t take away its ethical value
